{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:37Z","timestamp":1786112797576,"version":"build-2736575974"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["B2025201034"],"award-info":[{"award-number":["B2025201034"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008047","name":"Hebei University","doi-asserted-by":"publisher","award":["DXK202215"],"award-info":[{"award-number":["DXK202215"]}],"id":[{"id":"10.13039\/501100008047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008047","name":"Hebei University","doi-asserted-by":"publisher","award":["QNTD202406"],"award-info":[{"award-number":["QNTD202406"]}],"id":[{"id":"10.13039\/501100008047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008047","name":"Hebei University","doi-asserted-by":"publisher","award":["IT2023C01"],"award-info":[{"award-number":["IT2023C01"]}],"id":[{"id":"10.13039\/501100008047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drudis.2026.104674","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:59:43Z","timestamp":1776383983000},"page":"104674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting S1P signaling for drug development"],"prefix":"10.1016","volume":"31","author":[{"given":"Yaru","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9962-6369","authenticated-orcid":false,"given":"Kan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104674_b0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104674_b0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/acs.jmedchem.0c01664","article-title":"Small molecule inhibitors targeting biosynthesis of ceramide, the central hub of the sphingolipid network","volume":"64","author":"Sk\u00e1cel","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0015","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.1176709","article-title":"Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate","volume":"325","author":"Hait","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104674_b0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/scisignal.aaa4998","article-title":"Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation","volume":"8","author":"Panneer Selvam","year":"2015","journal-title":"Sci Signal"},{"key":"10.1016\/j.drudis.2026.104674_b0025","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/nature09128","article-title":"Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2","volume":"465","author":"Alvarez","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104674_b0030","article-title":"TRAF2 regulates TNF and NF-\u03baB signalling to suppress apoptosis and skin inflammation independently of sphingosine kinase 1","volume":"4","author":"Temadi","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2026.104674_b0035","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar5551","article-title":"Sphingosine 1-phosphate: lipid signaling in pathology and therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104674_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104469","article-title":"Clinical status and CNS adverse drug report of sphingosine-1-phosphate receptor modulators in multiple sclerosis","volume":"30","author":"Haldar","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104674_b0045","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104674_b0050","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.molmed.2017.07.001","article-title":"Sphingosine kinase 1: a potential therapeutic target in pulmonary arterial hypertension?","volume":"23","author":"Pyne","year":"2017","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.drudis.2026.104674_b0055","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1164\/rccm.201401-0121OC","article-title":"The sphingosine kinase 1\/sphingosine-1-phosphate pathway in pulmonary arterial hypertension","volume":"190","author":"Chen","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2026.104674_b0060","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3390\/ijms18091891","article-title":"'Dicing and splicing' sphingosine kinase and relevance to cancer","volume":"18","author":"Haddadi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104674_b0065","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.str.2013.02.025","article-title":"Molecular basis of sphingosine kinase 1 substrate recognition and catalysis","volume":"21","author":"Wang","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2026.104674_b0070","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.tibs.2016.02.007","article-title":"Sphingosine kinases: emerging structure-function insights","volume":"41","author":"Adams","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.drudis.2026.104674_b0075","doi-asserted-by":"crossref","first-page":"36318","DOI":"10.1074\/jbc.M504507200","article-title":"Involvement of N-terminal extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis","volume":"280","author":"Okada","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1021\/cb5008426","article-title":"Drugging sphingosine kinases","volume":"10","author":"Santos","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104674_b0085","first-page":"1394","article-title":"Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (Sk) isozymes, induce Sk1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells","volume":"4","author":"Byun","year":"2013","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0090","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1021\/jm900121d","article-title":"Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases","volume":"52","author":"Wong","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0095","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1016\/j.bmc.2005.02.053","article-title":"Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases","volume":"13","author":"Kim","year":"2005","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0100","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1039\/C8OB01867G","article-title":"Fluorinated triazole-containing sphingosine analogues. Syntheses and in vitro evaluation as SPHK inhibitors","volume":"16","author":"Escudero-Casao","year":"2018","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0105","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2008-02-138958","article-title":"A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia","volume":"112","author":"Paugh","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104674_b0110","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.biocel.2012.05.012","article-title":"Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b","volume":"44","author":"Lim","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.drudis.2026.104674_b0115","doi-asserted-by":"crossref","first-page":"18633","DOI":"10.1074\/jbc.M111.220756","article-title":"FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells","volume":"286","author":"Lim","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0120","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.cellsig.2011.05.010","article-title":"(R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells","volume":"23","author":"Lim","year":"2011","journal-title":"Cell Signal"},{"key":"10.1016\/j.drudis.2026.104674_b0125","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1039\/c3cc00181d","article-title":"Synthesis of selective inhibitors of sphingosine kinase 1","volume":"49","author":"Baek","year":"2013","journal-title":"Chem Commun"},{"key":"10.1016\/j.drudis.2026.104674_b0130","first-page":"5962","article-title":"Discovery and evaluation of inhibitors of human sphingosine kinase","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104674_b0135","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1021\/jm4011687","article-title":"Importance of sphingosine kinase (Sphk) as a target in developing cancer therapeutics and recent developments in the synthesis of novel Sphk inhibitors","volume":"57","author":"Plano","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0140","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1016\/j.bmcl.2013.06.030","article-title":"Structure guided design of a series of sphingosine kinase (Sphk) inhibitors","volume":"23","author":"Gustin","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104674_b0145","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1021\/acs.jmedchem.7b00070","article-title":"Discovery of a potent and selective sphingosine kinase 1 inhibitor through the molecular combination of chemotype-distinct screening hits","volume":"60","author":"Schnute","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0150","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1021\/ml5004074","article-title":"Crystal structure of sphingosine kinase 1 with PF-543","volume":"5","author":"Wang","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104674_b0155","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1021\/acs.jmedchem.9b00162","article-title":"Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2","volume":"62","author":"Adams","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.127900","article-title":"Investigating the binding mechanism of sphingosine kinase 1\/2 inhibitors: insights into subtype selectivity by homology modeling, molecular dynamics simulation and free energy calculation studies","volume":"1208","author":"Zhang","year":"2020","journal-title":"J Mol Struct"},{"key":"10.1016\/j.drudis.2026.104674_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115941","article-title":"Lipophilic tail modifications of 2-(hydroxymethyl) pyrrolidine scaffold reveal dual sphingosine kinase 1 and 2 inhibitors","volume":"30","author":"Li","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0170","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1021\/acs.jmedchem.2c00040","article-title":"Novel sphingosine kinase 1 inhibitor suppresses growth of solid tumor and inhibits the lung metastasis of triple-negative breast cancer","volume":"65","author":"Zhang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0175","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1021\/jm901860h","article-title":"Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors","volume":"53","author":"Mathews","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0180","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1016\/j.bmc.2009.04.015","article-title":"Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs","volume":"17","author":"Foss","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0185","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1021\/jm2001053","article-title":"Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells","volume":"54","author":"Kennedy","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1042\/BJ20120609","article-title":"Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate","volume":"447","author":"Kharel","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2026.104674_b0195","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/jm501760d","article-title":"Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors","volume":"58","author":"Patwardhan","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/acsmedchemlett.5b00304","article-title":"Structure-activity relationship studies and molecular modeling of naphthalene-based sphingosine kinase 2 inhibitors","volume":"7","author":"Congdon","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104674_b0205","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1021\/acs.jmedchem.7b00233","article-title":"Transforming sphingosine kinase 1 inhibitors into dual and sphingosine kinase 2 selective inhibitors: design, synthesis, and in vivo activity","volume":"60","author":"Childress","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112713","article-title":"Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors","volume":"206","author":"Tangadanchu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0215","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/acs.jmedchem.9b01508","article-title":"Discovery of a small side cavity in sphingosine kinase 2 that enhances inhibitor potency and selectivity","volume":"63","author":"Sibley","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0220","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.115.225862","article-title":"Sphingosine kinase 2 inhibition and blood sphingosine 1-phosphate levels","volume":"355","author":"Kharel","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104674_b0225","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1086\/687766","article-title":"Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension","volume":"6","author":"Gairhe","year":"2016","journal-title":"Pulm Circ"},{"key":"10.1016\/j.drudis.2026.104674_b0230","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/s41388-020-1352-y","article-title":"SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104674_b0235","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.3390\/ijms24108508","article-title":"Sphingosine kinases at the intersection of pro-inflammatory LPS and anti-inflammatory endocannabinoid signaling in BV2 mouse microglia cells","volume":"24","author":"Standoli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104674_b0240","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.matbio.2021.05.003","article-title":"Loss of sphingosine kinase 2 enhances Wilms tumor suppressor gene 1 and nephrin expression in podocytes and protects from streptozotocin-induced podocytopathy and albuminuria in mice","volume":"98","author":"Imeri","year":"2021","journal-title":"Matrix Biol"},{"key":"10.1016\/j.drudis.2026.104674_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109881","article-title":"Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis","volume":"79","author":"Schwalm","year":"2021","journal-title":"Cell Signal"},{"key":"10.1016\/j.drudis.2026.104674_b0250","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1016\/j.bmcl.2009.09.022","article-title":"Discovery of novel sphingosine kinase 1 inhibitors","volume":"19","author":"Xiang","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104674_b0255","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1016\/j.bmcl.2010.06.019","article-title":"Discovery of novel sphingosine kinase-1 inhibitors. Part 2","volume":"20","author":"Xiang","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104674_b0260","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.109.163444","article-title":"Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2","volume":"333","author":"French","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104674_b0265","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/DDDT.S367612","article-title":"Recent progress in the development of Opaganib for the treatment of Covid-19","volume":"16","author":"Smith","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2026.104674_b0270","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1535-7163.MCT-15-0279","article-title":"The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo","volume":"14","author":"Venant","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104674_b0275","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1210\/en.2010-0420","article-title":"Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640","volume":"151","author":"Antoon","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2026.104674_b0280","article-title":"Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-proylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104674_b0285","doi-asserted-by":"crossref","first-page":"47281","DOI":"10.1074\/jbc.M306896200","article-title":"Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial growth factor-induced vascular permeability","volume":"278","author":"Sanchez","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.167829","article-title":"Study on the synthesis, characterization, and antitumor mechanism investigation of QZQ-01115 via targeting sphingosine kinase 2","volume":"1871","author":"Liu","year":"2025","journal-title":"BBA Mol Basis Dis"},{"key":"10.1016\/j.drudis.2026.104674_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103414","article-title":"Design of new quinolin-2-one-pyrimidine hybrids as sphingosine kinases inhibitors","volume":"94","author":"Vettorazzi","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.carres.2019.06.016","article-title":"Synthetic analogues of marine cytotoxic jaspine B and its stereoisomers","volume":"482","author":"Martinkov\u00e1","year":"2019","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.drudis.2026.104674_b0305","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1016\/j.bmc.2011.07.061","article-title":"Pachastrissamine (jaspine B) and its stereoisomers inhibit sphingosine kinases and atypical protein kinase C","volume":"19","author":"Yoshimitsu","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103369","article-title":"Synthesis and biological evaluation of 2-epi-jaspine B analogs as selective sphingosine kinase 1 inhibitors","volume":"98","author":"Yang","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0315","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7164\/antibiotics.53.459","article-title":"F-12509a, a new sphingosine kinase inhibitor, produced by a discomycete","volume":"53","author":"Kono","year":"2000","journal-title":"J Antibiot"},{"key":"10.1016\/j.drudis.2026.104674_b0320","doi-asserted-by":"crossref","first-page":"415","DOI":"10.7164\/antibiotics.54.415","article-title":"S-15183a and b, new sphingosine kinase inhibitors, produced by a fungus","volume":"54","author":"Kono","year":"2001","journal-title":"J Antibiot"},{"key":"10.1016\/j.drudis.2026.104674_b0325","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7164\/antibiotics.53.753","article-title":"B-535a, b and c, new sphingosine kinase inhibitors, produced by a marine bacterium; taxonomy, fermentation, isolation, physico-chemical properties and structure determination","volume":"53","author":"Kono","year":"2000","journal-title":"J Antibiot"},{"key":"10.1016\/j.drudis.2026.104674_b0330","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7164\/antibiotics.53.759","article-title":"Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium","volume":"53","author":"Kono","year":"2000","journal-title":"J Antibiot"},{"key":"10.1016\/j.drudis.2026.104674_b0335","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-07-2322","article-title":"Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models","volume":"7","author":"Pchejetski","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104674_b0340","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1089\/dna.2015.2959","article-title":"Activation of SphK1 by K6PC-5 inhibits oxygen-glucose deprivation\/reoxygenation-induced myocardial cell death","volume":"34","author":"Shao","year":"2015","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.drudis.2026.104674_b0345","doi-asserted-by":"crossref","first-page":"22800","DOI":"10.18632\/oncotarget.15205","article-title":"Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104674_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109245","article-title":"Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: a targeted approach towards anticancer therapy","volume":"118","author":"Gupta","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2026.104674_b0355","doi-asserted-by":"crossref","first-page":"21550","DOI":"10.1021\/acsomega.0c02165","article-title":"Discovery of harmaline as a potent inhibitor of sphingosine kinase 1: a chemopreventive role in lung cancer","volume":"5","author":"Roy","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2026.104674_b0360","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1080\/07391102.2021.1882341","article-title":"Investigation of sphingosine kinase 1 inhibitory potential of cinchonine and colcemid targeting anticancer therapy","volume":"40","author":"Roy","year":"2022","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.drudis.2026.104674_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127036","article-title":"Investigating potential of cholic acid, syringic acid, and mangiferin as cancer therapeutics through sphingosine kinase 1 inhibition","volume":"253","author":"Shakeel","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104674_b0370","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.18632\/oncotarget.3178","article-title":"A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties","volume":"6","author":"Pitman","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104674_b0375","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1021\/acs.molpharmaceut.3c00078","article-title":"Targeting acute myeloid leukemia using sphingosine kinase 1 inhibitor-loaded liposomes","volume":"20","author":"Nguyen","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104674_b0380","article-title":"Characterization of isoenzyme-selective inhibitors of human sphingosine kinases","volume":"7","author":"Gao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104674_b0385","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molimm.2018.08.025","article-title":"Biological function of Spns2: from zebrafish to human","volume":"103","author":"Zhu","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1016\/j.drudis.2026.104674_b0390","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature24053","article-title":"Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets","volume":"550","author":"Vu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104674_b0395","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1021\/acs.jmedchem.1c02171","article-title":"Discovery of in vivo active sphingosine-1-phosphate transporter (Spns2) inhibitors","volume":"65","author":"Fritzemeier","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2681","article-title":"Sphingosine 1-phosphate signaling in perivascular cells enhances inflammation and fibrosis in the kidney","volume":"14","author":"Tanaka","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104674_b0405","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1021\/acs.jmedchem.3c00149","article-title":"2-aminobenzoxazole derivatives as potent inhibitors of the sphingosine-1-phosphate transporter spinster homolog 2 (Spns2)","volume":"66","author":"Burgio","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129516","article-title":"Imidazole-based sphingosine-1-phosphate transporter Spns2 inhibitors","volume":"96","author":"Shrader","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104674_b0415","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.cell.2023.04.028","article-title":"Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate","volume":"186","author":"Chen","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104674_b0420","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ibd\/izz174","article-title":"Sphingosine-1-phosphate lyase inhibition alters the S1P gradient and ameliorates Crohn\u2019s-like ileitis by suppressing thymocyte maturation","volume":"26","author":"Karuppuchamy","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.drudis.2026.104674_b0425","doi-asserted-by":"crossref","first-page":"H1753","DOI":"10.1152\/ajpheart.00946.2010","article-title":"S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart","volume":"300","author":"Bandhuvula","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.drudis.2026.104674_b0430","first-page":"555","article-title":"Component of caramel food coloring, THI, causes lymphopenia indirectly via a key metabolic intermediate","volume":"23","author":"Ohtoyo","year":"2016","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2026.104674_b0435","doi-asserted-by":"crossref","first-page":"8650","DOI":"10.1021\/jm101183p","volume":"53","author":"Bagdanoff","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0440","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1021\/jm900278w","article-title":"Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders","volume":"52","author":"Bagdanoff","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0445","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1126\/science.1113640","article-title":"Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients","volume":"309","author":"Schwab","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104674_b0450","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/pgmj.73.864.617","article-title":"Pyridoxine deficiency: new approaches in immunosuppression and chemotherapy","volume":"73","author":"Trakatellis","year":"1997","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.drudis.2026.104674_b0455","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0278-6915(88)90119-6","article-title":"The effect of pyridoxine on the number of lymphocytes in the blood of rats fed caramel colour (III)","volume":"26","author":"Sinkeldam","year":"1988","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.drudis.2026.104674_b0460","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1021\/jm500338n","article-title":"Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-ylnicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis","volume":"57","author":"Weiler","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059630","article-title":"Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis","volume":"8","author":"Billich","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104674_b0470","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/acs.joc.9b02420","article-title":"A mechanism-based sphingosine-1-phosphate lyase inhibitor","volume":"85","author":"Pons","year":"2020","journal-title":"J Org Chem"},{"key":"10.1016\/j.drudis.2026.104674_b0475","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.drudis.2026.104674_b0480","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:15:44Z","timestamp":1785946544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1359644626000796"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104674","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting S1P signaling for drug development","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104674"}}